Sequent Scientific , a prominent player in the pharmaceutical industry , has reached a significant milestone in its proposed merger with Viyash. The company announced that it has successfully obtained approvals from the stock exchanges for this strategic move, marking a crucial step forward in the consolidation process.

Merger Progress

Sequent Scientific has cleared a major hurdle in its merger plans with Viyash, securing the necessary approvals from the stock exchanges. This development paves the way for the next phase of the merger process, demonstrating the company's commitment to its strategic growth initiatives.

NCLT Filing

Following the stock exchange approvals, Sequent Scientific has taken the next step by filing for clearance with the National Company Law Tribunal (NCLT). This filing is a critical component of the merger process, as the NCLT's approval is essential for the legal consolidation of the two entities.

Implications of the Merger

The merger between Sequent Scientific and Viyash is expected to have significant implications for both companies. While specific details of the merger's benefits are not provided in the current announcement, such strategic moves are typically aimed at:

• Enhancing operational synergies
• Expanding market presence
• Improving financial performance
• Strengthening the combined entity's competitive position in the pharmaceutical sector

Next Steps

With the stock exchange approvals secured and the NCLT filing completed, the focus now shifts to obtaining the tribunal's clearance. Shareholders and market observers will be keenly watching for further developments in this merger process, as it could potentially reshape Sequent Scientific's market position and future prospects.

As the merger proceedings continue, Sequent Scientific is expected to provide further updates on the progress and any significant developments that may arise during the NCLT review process.

Note: Investors are advised to keep track of official communications from the company for the most up-to-date information on the merger process and its potential impacts.

SeQuent Scientific , a leading player in the animal health sector, has reported a significant improvement in its financial performance for the recent financial year, marking a strong turnaround from the previous year's losses.

Full Year Performance

SeQuent Scientific reported a net profit of ₹44.3 crore for the recent financial year, recovering from a ₹54.6 crore loss in the previous year. The company's revenue grew by 13.3% to ₹1551.40 crore. This impressive turnaround can be attributed to strategic restructuring efforts and improved performance of its subsidiaries.

Quarterly Performance

For the most recent quarter, the company posted a net profit of ₹16.3 crore, further solidifying its recovery.

Revenue Growth

The company announced a robust increase in quarterly revenue, which climbed to ₹400.00 crore in the recent quarter, up from ₹360.00 crore in the same period last year. This 11.11% year-over-year growth demonstrates the company's ability to expand its market presence and drive sales despite challenging market conditions.

EBITDA and Margin Improvement

The company's operational efficiency saw a marked enhancement, reflected in its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) figures:

The substantial increase in EBITDA, rising from ₹32.30 crore to ₹46.20 crore, represents a 43.0% year-over-year growth. More importantly, the EBITDA margin expanded by 258 basis points, reaching 11.51% compared to 8.93% in the same quarter last year. This improvement in margin indicates enhanced operational efficiency and cost management.

Dividend

Despite the strong financial performance, the company has not declared any dividend for the recent financial year.

Conclusion

SeQuent Scientific's recent financial results paint a picture of a company on a strong upward trajectory. The combination of significant revenue growth, a substantial return to profitability, and improved operational metrics suggests that the company's strategic initiatives are yielding positive results. As SeQuent Scientific continues to navigate the dynamic animal health market, investors and industry observers will be keen to see if this positive momentum can be sustained in the coming periods.